|
OBESITY
Dietary supplements, food based bioactive ingredients, and
ultimately pharmaceuticals to be developed for the prevention of body fat
accumulation. It is anticipated that the bioactive supplement, owing to its
inhibitory effects and safety profile, will provide utility in other large
markets which are currently un-served and under-served. Examples of such
additional outlets include childhood obesity and military personnel.
|
|
|
CANCER
Nutra – therapeutical products will be developed to focus on
cancer, providing needed bioactive nutrients to speed patient recovery.
Additionally, it is expected that prevention of metastasis can be achieved
through selective targeting of cancer cells through FATEK’s targeted
metabolic pathway.
|
INDICATION |
Lead
Discovery |
Preclinical |
Phase I |
Phase II |
Phase III |
|
Pharmaceuticals |
|
Obesity
Type II Diabetes
|
 |
|
Infertility
|
|
|
Nutraceuticals |
|
Overweight and Obesitythrough the
Metabolic Regulation (modulated energy
utilization, enhanced immune system
defense and muscle development)
|
|
|
Cancer prevention
|
|
|
|
